Learn how advanced cell therapies and technology are transforming how the world’s most challenging conditions are treated. Integrated solutions, with automation from development to manufacturing, continue to help shape personalized medicine and enhance therapeutic precision.
In an era defined by rapid technological advancement, the global healthcare landscape is undergoing a dramatic transformation, driven by innovations in personalized medicine. With healthcare challenges like cancer and genetic disorders affecting millions, the need for accessible and effective therapies has never been more crucial. As highlighted by leading organizations during high-profile discussions at forums like the United Nations, the Fourth Industrial Revolution offers unprecedented opportunities to revolutionize treatments and patient access worldwide.
At the forefront of this revolution is miDiagnostics, a pioneering spin-out from Imec, in collaboration with esteemed institutions such as Johns Hopkins University. Our mission centers on enhancing cancer treatment and addressing various illnesses through advanced cell therapies and immunotherapies, leveraging cutting-edge silicon technologies.
A vital partner in our journey is Thermo Fisher Scientific, a global leader in serving science. Thermo Fisher plays a pivotal role in our mission by providing comprehensive solutions from research and development to clinical and commercial manufacturing. Their scalable manufacturing technologies not only accelerate the transition of cell therapies from the laboratory bench to bedside but also ensure that they meet the rigorous standards required for patient care.
Thermo Fisher’s expertise in logistics and commercialization is essential to our shared goal of delivering life-saving therapies to those in need. “As collaborators, our aim is to bridge the gap between scientific discovery and patient-ready therapies, ensuring that cutting-edge treatments reach the individuals who will benefit from them most,” stated Jean Luo, VP and General Manager Purification and Pharma Analytics Thermo Fisher Scientific.
At miDiagnostics, we emphasize automation and scaling in our operations, enabling rapid and efficient manufacturing processes that are pivotal for the timely delivery of high-quality therapeutic solutions. Our innovative approach also facilitates the miniaturization and decentralization of diagnostic tools, allowing for near-patient testing. This not only enhances the speed, but also makes healthcare more accessible to patients who need it the most.
Furthermore, Thermo Fisher’s commitment to developing market-leading solutions in sterility assays increases the speed of manufacturing while reducing overall risk and costs, addressing critical challenges in the production of CAR T-cell therapies.
However, challenges remain. The high costs associated with cell therapies—often nearing $500,000 per patient—hinder widespread access. The 2020 statistic revealing that only 3,000 of the 500,000 eligible patients received CAR T-cell therapies underscores a critical gap in treatment availability that we aim to address through our partnership.
“It is essential that we not only innovate, but also optimize manufacturing processes to increase accessibility and reduce costs,” added Katleen Verleysen, CEO miDiagnostics.
As we look to the future, the innovations and collaborative solutions developed by miDiagnostics and Thermo Fisher represent a crucial step toward overcoming the obstacles that currently limit patient access to advanced therapies. By harnessing cutting-edge technologies and fostering partnerships within the healthcare ecosystem, we are committed to transforming treatment paradigms.
“Through this commitment, we aspire to create a world where life-saving immunotherapies are available to all who need them, ultimately leading to better health outcomes and a more sustainable healthcare model. This journey toward revolutionizing cell therapies is just beginning, and with Thermo Fisher by our side, the future of personalized medicine looks promising”, added Katleen Verleysen, CEO miDiagnostics.
Find out more about DAVOS 2025 Campaign
